EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. We are focusing on chronic respiratory diseases with initial clinical trials planned in 2020.

The company is seed-funded, privately held and in late preclinical development.


Research at EpiEndo Pharmaceuticals focuses on finding ways to strengthen epithelial tissues using novel drugs. Based on the existing commercial macrolide azithromycin, we are finding ways to create new treatments for chronic airway diseases, with applications for other epithelial tissues.

The research team at EEP has over a decade´s experience studying the lungs and the effects of the macrolide antibiotic, azithromycin (Asgrimsson et al. 2006. Antimicrobial Agents and Chemotherapy, 50:1805-12., Halldorsson et al. 2007. In Vitro Cell Develop Biol, 43:283-89., Halldorsson et al. 2010. Am J Resp Cell Mol Biol, 42:62-8.). Patients receiving azithromycin showed reduced hospital admissions, and our studies demonstrate that azithromycin could enhance barrier strength at the cellular level.

Our current focus is to develop novel and proprietary drugs that preserve the barrier enhancing effects of azithromycin but lack the antibiotic activity. The cellular response to these new drugs are the key focus, ranging from how they enhance the cellular barrier of the lungs to the response generated by the cells, which contribute to improved lung function.


Fredrik Lehmann, PhD.

Fredrik has a PhD degree in Medicinal Chemistry from the University  of Gothenburg and has extensive experience having worked on various drug projects in different phases of development. In addition to being the CEO of EpiEndo, Fredrik holds the position as Head of Research and CMC at Oncopeptides AB in Stockholm, Sweden.


Dr. Friðrik Rúnar Garðarsson, MD
Founder & Board member

Friðrik Rúnar (MD) graduated from the University of Iceland in 2010, finishing his internship in 2011. Most of his clinical work has been in pediatrics and neonatology as well as anesthesia and pulmonary intensive care. His clinical work has led him to deal mainly with patients who suffer from both chronic and acute airway diseases. Since 2007, has been working towards forming the hypotheses on which EpiEndo’s compound development and novel research is based. Friðrik’s research initiative and scientific innovation led to the founding of EpiEndo Pharmaceuticals ehf. in 2014.


Professor Thorarinn Gudjonsson, PhD
Head of in vitro research

Thorarinn has a PhD from the University of Copenhagen. He is now a professor at the University of Iceland and leads the Stem Cell research unit at Biomedical Center at University of Iceland.


Olafur Baldursson, MD, PhD
Medical Director

Ólafur is pulmonologist trained at the University Hospital in Iowa City at the Michael J Welsh Laboratory. He also has a PhD from the University of Iceland where he researched lung epithelium. 
He is the Medical Director at the University Hospital in Iceland. 

oli bald greyscale.nobackground.png

Finnur Friðrik Einarsson

Finnur Friðrik Einarsson is an experienced project manager with engineering degrees in Industrial Engineering from the University of Iceland and Engineering Management from Reykjavik University. He has more than 15 years of experience as a technical consultant and was previously a General Manager for an Icelandic SME software company with its headquarters in Iceland servicing companies across multiple regions.


Board members

Professor Clive Page, OBE - Chairman

Dr. Friðrik Rúnar Garðarsson, Founder of EpiEndo Pharmaceuticals ehf.

Hjalmar Skarphedinsson, PhD

Magnus Berg Magnusson

Dr. Olafur Baldursson


Scientific advisory board

Professor Gudmundur Hrafn Gudmundsson, University of Iceland

Professor Magnus Karl Magnusson, University of Iceland

Dr. Olafur Baldursson, University Hospital of Iceland

Dr. Sigurbergur Karason, University Hospital of Iceland

Professor Thorarinn Gudjonsson, University of Iceland



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 761828

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 761828



Fredrik Lehmann, CEO


EpiEndo Pharmaceuticals ehf

Borgartún 28

105 Reykjavík



Please complete the form below

Name *